{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:55:18Z","timestamp":1762509318099,"version":"build-2065373602"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bevacizumab, an anti-VEGF agent commonly employed in cancer therapy, can induce renal vascular endothelial and podocyte damage by inhibiting VEGF, leading to renal disease. We present a case of nephrotic syndrome and renal insufficiency arising from small intestinal mucinous adenocarcinoma 17 years post-renal transplantation, treated with bevacizumab and sindilizumab. Renal biopsy confirmed renal-limited thrombotic microangiopathy (TMA) with FSGS-like lesions in the transplanted kidney, attributed to bevacizumab. Upon discontinuation of the antitumor drugs and initiation of treatment with telmisartan, fenoldopam, and ambrisentan, proteinuria markedly decreased and eGFR improved. No tumor recurrence was observed over a follow-up period exceeding six months.<\/jats:p>","DOI":"10.3389\/fonc.2025.1638274","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:10:50Z","timestamp":1759723850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Bevacizumab-induced renal-limited TMA and FSGS-like lesions in a kidney transplant recipient"],"prefix":"10.3389","volume":"15","author":[{"given":"Xingxing","family":"Jian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2019.10.002","article-title":"Focus on the occurrence, diagnosis and individualized treatment of tumors after renal transplantation","volume":"99","author":"Chen","year":"2019","journal-title":"Zhonghua yi xue za zhi"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000525029","article-title":"Onconephrology: update in anticancer drug-related nephrotoxicity","volume":"147","author":"Garc\u00eda-Carro","year":"2023","journal-title":"Nephron"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol: JASN"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.168996","article-title":"Experience of bevacizumab in a patient with colorectal cancer after renal transplantation","volume":"11","author":"M\u00fcsri","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010064","article-title":"Angiogenesis inhibitors as anti-cancer therapy following renal transplantation: A case report and review of the literature","volume":"28","author":"Kasherman","year":"2021","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019-0423","article-title":"Post renal-transplant Malignancy surveillance","volume":"20","author":"Manickavasagar","year":"2020","journal-title":"Clin Med (Lond Engl)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.10.015","article-title":"Minimizing the risk of posttransplant Malignancy","volume":"40","author":"Campistol","year":"2008","journal-title":"Transplant Proc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/ckj\/sfy114","article-title":"Pembrolizumab-related renal toxicities: diagnosis first, treatment later","volume":"12","author":"Sprangers","year":"2019","journal-title":"Clin Kidney J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-02087-3","article-title":"Lessons for the clinical nephrologist: legacy effects of bevacizumab and ramucirumab lead to nephrotic syndrome due to renal-limited thrombotic microangiopathy with podocytopathy","volume":"37","author":"Iwasaki","year":"2024","journal-title":"J Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8365-21","article-title":"Thrombotic microangiopathy, podocytopathy, and damage to the renal tubules with severe proteinuria and acute renal dysfunction induced by lenvatinib","volume":"61","author":"Nakashima","year":"2022","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e220078","DOI":"10.1530\/EO-22-0078","article-title":"Thrombotic microangiopathy associated with lenvatinib therapy","volume":"3","author":"Contreras Angulo","year":"2023","journal-title":"Endocr Oncol (Bristol Engl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1188\/13.CJON.425-433","article-title":"Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer","volume":"17","author":"Grenon","year":"2013","journal-title":"Clin J Oncol Nurs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03114-5","article-title":"Lenvatinib-related renal microangiopathy: a case series","volume":"480","author":"Delsante","year":"2022","journal-title":"Virchows Archiv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000510141","article-title":"Podocyte involvement in renal thrombotic microangiopathy: A clinicopathological study","volume":"51","author":"Hu","year":"2020","journal-title":"Am J Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in igA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504623","article-title":"The role of endothelin and endothelin antagonists in chronic kidney disease","volume":"6","author":"Raina","year":"2020","journal-title":"Kidney Dis (Basel Switzerland)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet (Lond Engl)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet (Lond Engl)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1638274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:10:52Z","timestamp":1759723852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1638274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":22,"alternative-id":["10.3389\/fonc.2025.1638274"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1638274","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"article-number":"1638274"}}